AU2021327241A1 - Stereoselective manufacture of selected purine phosphoramidates - Google Patents

Stereoselective manufacture of selected purine phosphoramidates Download PDF

Info

Publication number
AU2021327241A1
AU2021327241A1 AU2021327241A AU2021327241A AU2021327241A1 AU 2021327241 A1 AU2021327241 A1 AU 2021327241A1 AU 2021327241 A AU2021327241 A AU 2021327241A AU 2021327241 A AU2021327241 A AU 2021327241A AU 2021327241 A1 AU2021327241 A1 AU 2021327241A1
Authority
AU
Australia
Prior art keywords
compound
formula
alkyl
hydrogen
afford
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327241A
Other languages
English (en)
Inventor
Narayan Chaudhuri
Adel Moussa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atea Pharmaceuticals Inc
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of AU2021327241A1 publication Critical patent/AU2021327241A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Luminescent Compositions (AREA)
AU2021327241A 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates Pending AU2021327241A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063067726P 2020-08-19 2020-08-19
US63/067,726 2020-08-19
US202063074302P 2020-09-03 2020-09-03
US63/074,302 2020-09-03
US202063094759P 2020-10-21 2020-10-21
US63/094,759 2020-10-21
US202063129306P 2020-12-22 2020-12-22
US63/129,306 2020-12-22
PCT/US2021/046778 WO2022040473A1 (en) 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates

Publications (1)

Publication Number Publication Date
AU2021327241A1 true AU2021327241A1 (en) 2023-04-20

Family

ID=80323295

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327241A Pending AU2021327241A1 (en) 2020-08-19 2021-08-19 Stereoselective manufacture of selected purine phosphoramidates

Country Status (9)

Country Link
US (1) US20230331751A1 (cg-RX-API-DMAC7.html)
EP (1) EP4200309A4 (cg-RX-API-DMAC7.html)
JP (2) JP7851034B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230053640A (cg-RX-API-DMAC7.html)
CN (1) CN115884977A (cg-RX-API-DMAC7.html)
AU (1) AU2021327241A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173661A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023002064A (cg-RX-API-DMAC7.html)
WO (1) WO2022040473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
AU2022291927A1 (en) 2021-06-17 2024-01-04 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
CN116462728B (zh) * 2021-12-15 2023-12-12 南京知和医药科技有限公司 一种抗病毒感染的嘌呤核苷衍生物及其药物组合物和用途
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CN121628124B (zh) * 2026-02-05 2026-04-10 山东鲁源化工科技有限公司 一种高热稳定性聚磷酸酯阻燃剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2870169A1 (en) * 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
FI3265102T3 (fi) * 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
PT3512863T (pt) * 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19

Also Published As

Publication number Publication date
JP7851034B2 (ja) 2026-04-24
JP2023538594A (ja) 2023-09-08
US20230331751A1 (en) 2023-10-19
JP2026117077A (ja) 2026-07-14
CN115884977A (zh) 2023-03-31
TW202214260A (zh) 2022-04-16
MX2023002064A (es) 2023-03-16
KR20230053640A (ko) 2023-04-21
EP4200309A1 (en) 2023-06-28
EP4200309A4 (en) 2025-03-19
CA3173661A1 (en) 2022-02-24
WO2022040473A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
EP4200309A1 (en) Stereoselective manufacture of selected purine phosphoramidates
US12583883B2 (en) Asymmetric auxiliary group
AU2021290235B2 (en) Chiral reagents for preparation of homogeneous oligomers
CA2934531C (en) Process methods for phosphatidylinositol 3-kinase inhibitors
EP3172218B1 (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
EP3458452B1 (en) Heterocyclic compounds useful as anti-bacterial agents and method for production
ES3034982T3 (en) Method of manufacturing a solid form of a bet bromodomain inhibitor
JP2020183374A (ja) リン酸エステルの新規合成法
ES2706699T3 (es) Preparación de tesetaxel y compuestos relacionados y los compuestos intermedios de síntesis correspondientes
EP4479381A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
EP2625181B1 (en) Method of preparation of antiviral compounds and useful intermediates thereof
WO2020246443A1 (ja) 二分岐脂質結合オリゴヌクレオチドの製造方法及び中間体
JP7433684B1 (ja) 疑似固相保護基、それを用いたヌクレオシド保護体又はオリゴヌクレオチド保護体、オリゴアミダイト前駆体の製造方法
CA3245127A1 (en) BIS-PROTECTED ACTIVATED GUANINE MONOMERS
WO2017191608A1 (en) Novel process for preparation of idelalisib
WO2025080631A1 (en) Process for making a kras g12c inhibitor
HK1232546B (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
HK1232546A1 (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate